The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis

BACKGROUND: Irinotecan (IRI)-based and oxaliplatin (OXA)-based regimens are available for the treatment of metastatic colorectal cancer (mCRC). Several studies have published inconsistent results in their comparisons of the efficacy and toxicity of IRI ± bevacizumab and OXA ± bevacizumab. This meta-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Jiali, Chen, Yuetong, Gong, Yang, Wei, Jingsun, Cui, Xiaowen, Yu, Hualin, Zhao, Wenjing, Gu, Dongying, Chen, Jinfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775432/
https://www.ncbi.nlm.nih.gov/pubmed/31574891
http://dx.doi.org/10.1097/MD.0000000000017384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775432/
https://www.ncbi.nlm.nih.gov/pubmed/31574891
http://dx.doi.org/10.1097/MD.0000000000017384

Ejemplares similares